We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
- Authors
Atik, Alp; Yijun Hu; Honghua Yu; Chun Yang; Bin Cai; Yijing Tao; Dongli Li; Yan Chen; Li Lu; Guodong Li; Ling Yuan; Hu, Yijun; Yu, Honghua; Yang, Chun; Cai, Bin; Tao, Yijing; Li, Dongli; Chen, Yan; Lu, Li; Li, Guodong
- Abstract
<bold>Background: </bold>To evaluate the macular sensitivity changes after half-dose photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSCR).<bold>Methods: </bold>Eighteen patients (26 eyes) with chronic CSCR were recruited in the same hospital between April 2011 and December 2012. All patients were treated with one session of half-dose PDT after complete ophthalmic examination. Macular sensitivity examination was performed at baseline and 1, 3 and 6 months post-treatment. Mean sensitivity (MS) of the central 10 degrees (10°) and 4 degrees (4°), mean deviation (MD) and pattern standard deviation (PSD) on automated static perimetry (Humphrey Field Analyzer II-750) were used for analysis.<bold>Results: </bold>There was significant improvement of the 10°MS from baseline (29.76 ± 1.51 dB) to 1 month (31.74 ± 1.56 dB), 3 months (31.51 ± 1.38 dB) and 6 months (31.19 ± 1.61 dB) after treatment (P < 0.001). The 4°MS was also significantly improved with half-dose PDT from baseline (28.96 ± 1.78 dB) to 1 month (32.41 ± 1.66 dB), 3 months (32.46 ± 1.50 dB) and 6 months (31.90 ± 1.84 dB) post-treatment (P < 0.001). MD was improved from baseline (-3.39 ± 0.89 dB) to 1 month (-1.96 ± 0.29 dB), 3 months (-1.94 ± 0.29 dB) and 6 months (-2.45 ± 0.13) post-treatment (P = 0.004). PSD also improved from 1.97 ± 0.24 dB at baseline to 1.47 ± 0.27 dB, 1.34 ± 0.24 dB, and 1.53 ± 0.24 dB (P = 0.001) at 1, 3 and 6 months after treatment, respectively.<bold>Conclusion: </bold>Macular sensitivity in CSCR can be improved by half-dose PDT, along with improvement of visual acuity and retinal thickness. The treatment outcome at 1 month may be a predictor of the final treatment response.
- Subjects
EYE diseases; PHOTODYNAMIC therapy; VERTEPORFIN; DRUG efficacy; DIAGNOSIS; PATIENTS; PHOTOSENSITIZERS; PORPHYRINS; ANALYSIS of variance; ANGIOGRAPHY; PERIMETRY; PHOTOCHEMOTHERAPY; RETINAL diseases; VISUAL acuity; VISUAL fields; OPTICAL coherence tomography; THERAPEUTICS
- Publication
BMC Ophthalmology, 2017, Vol 17, p1
- ISSN
1471-2415
- Publication type
journal article
- DOI
10.1186/s12886-017-0535-y